EMBC — Embecta Corp. Stock Price, Chart & AI Report

Neutral Aug 31, 2026 • 21:00 UTC GlobeNewswire Inc. • Na

embecta to Participate in Investor Events

Embecta Corp. (EMBC) announced that management will participate in investor events at the Wells Fargo 2026 Healthcare Conference on September 9, 2026, in Boston and the J.P. Morgan 4th Annual Nashville Healthcare Conference 2026 on September 10, 2026, where they will host fireside chats and one-on-one investor meetings.

EMBC investor conference healthcare Wells Fargo J.P. Morgan medical supplies insulin delivery

Sentiment note

The announcement is routine corporate communication about participation in investor conferences. While investor engagement is generally positive for shareholder relations, the news itself contains no material business developments, financial results, or strategic announcements that would warrant a positive or negative sentiment rating.

Negative Aug 10, 2026 • 13:47 UTC GlobeNewswire Inc. • Schall, Brown & Schwartz Llp

EMBC Investors Have Opportunity to Lead Embecta Corp. Securities Fraud Lawsuit with SBS Law

Schall, Brown & Schwartz LLP has filed a class action lawsuit against Embecta Corp. (NASDAQ: EMBC) for alleged violations of securities laws. The lawsuit claims the company made false and misleading statements regarding its fiscal guidance for Q2 and full-year 2026, failing to disclose known market headwinds in the pen needle sector. The class period runs from November 25, 2025 to May 4, 2026, with a deadline of August 17, 2026 for investors to participate.

EMBC class action lawsuit securities fraud false guidance market headwinds pen needle market shareholder rights Securities Exchange Act

Sentiment note

The company is accused of making false and misleading statements about its financial guidance and failing to disclose known market headwinds that would impact performance. These allegations of securities fraud and investor deception warrant a negative sentiment rating.

Negative Aug 7, 2026 • 18:52 UTC GlobeNewswire Inc. • Rosen Law Firm

ZILLOW DEADLINE: ROSEN, THE FIRST FILING FIRM, Encourages Zillow Group, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - Z, ZG

Rosen Law Firm is reminding investors in Zillow Group, Embecta Corp, and GoDaddy Inc. of upcoming lead plaintiff deadlines in securities class actions. The Zillow lawsuit alleges the company made false statements regarding its Redfin agreement and antitrust risks. Investors with losses exceeding $100K are encouraged to contact the firm before the respective deadlines.

Z ZG EMBC GDDY securities class action lead plaintiff deadline investor losses antitrust

Sentiment note

Company is involved in a securities class action with an August 17 deadline, indicating alleged investor losses and potential securities violations, though specific details are not provided in the excerpt.

Neutral Aug 7, 2026 • 10:30 UTC GlobeNewswire Inc. • Unknown

Embecta Corp. Reports Third Quarter Fiscal 2026 Financial Results

Embecta Corp. (NASDAQ: EMBC), a global medical supplies company with a 100-year legacy in insulin delivery, announced its third quarter fiscal 2026 financial results on August 7, 2026. The company hosted a conference call and webcast for analysts and investors to discuss the earnings.

EMBC Embecta Corp. Q3 2026 earnings insulin delivery medical supplies financial results

Sentiment note

The article is a standard earnings announcement that reports financial results without disclosing specific financial metrics, performance data, or forward-looking guidance. No positive or negative performance indicators are mentioned, making this a neutral informational disclosure.

Positive Aug 7, 2026 • 10:00 UTC GlobeNewswire Inc. • Na

embecta Announces Quarterly Cash Dividend

Embecta Corp. (EMBC) declared a quarterly cash dividend of $0.01 per share payable on September 15, 2026. The company also announced the appointment of Nimish Muzumdar as Senior Vice President and President of North America, effective June 15, 2026.

EMBC dividend quarterly cash dividend executive appointment North America insulin delivery medical supplies

Sentiment note

The company is returning capital to shareholders through a dividend declaration and strengthening leadership with a strategic executive appointment to a key regional position, both indicating operational confidence and shareholder-friendly management.

Negative Aug 6, 2026 • 02:31 UTC GlobeNewswire Inc. • Hagens Berman

EMBC 12-DAY DEADLINE ALERT: Embecta Corp. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – Hagens Berman

Hagens Berman is investigating Embecta Corp. (NASDAQ: EMBC) for allegedly misleading investors about the stability of its insulin pen needle business. The company claimed its pen needle portfolio was 'stable' and 'resilient' while experiencing significant competitive share loss and market volume softness. On May 5, 2026, Embecta revealed massive revenue declines, slashed full-year 2026 adjusted EPS guidance by 43%, and cut its quarterly dividend by 93%, causing the stock to plummet 57.8% in a single trading day. Investors with substantial losses during the class period (Nov. 25, 2025 – May 4, 2026) are encouraged to participate in the lawsuit with a lead plaintiff deadline of August 17, 2026.

EMBC securities class action misrepresentation insulin pen needle revenue decline dividend cut stock plunge investor losses

Sentiment note

The company is facing a securities class action lawsuit for allegedly misleading investors about business stability while experiencing significant revenue declines, competitive share loss, and market softness. The subsequent disclosure led to a 57.8% stock price decline, 43% EPS guidance reduction, and 93% dividend cut, indicating severe operational and financial deterioration.

Negative Aug 5, 2026 • 18:45 UTC GlobeNewswire Inc. • Law Offices Of Howard G. Smith

DEADLINE ALERT for ERAS, VIA, EMBC, Z: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions

Class action lawsuits have been filed against four publicly-traded companies alleging securities fraud. Erasca faces allegations regarding misleading preclinical data comparisons; Via Transportation failed to disclose declining ARR and regulatory issues; Embecta misrepresented guidance and segment weakness; and Zillow mischaracterized its Redfin agreement and downplayed antitrust risks. Investors have until mid-August 2026 to file lead plaintiff motions.

ERAS VIA EMBC Z securities fraud class action lawsuit misleading statements material disclosure

Sentiment note

Company issued misleading and unattainable guidance while failing to disclose segment weakness in the U.S. pen needle market affecting revenue projections.

Negative Aug 4, 2026 • 14:45 UTC GlobeNewswire Inc. • Suewallst

EMBC Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Embecta Corp. Securities Lawsuit - Contact SueWallSt

Embecta Corp. (NASDAQ: EMBC) faces a securities class action lawsuit for allegedly misleading investors about fiscal year 2026 performance. The company promised flat-to-down-2% revenue and $2.80-$3.00 EPS but delivered a 17.4% revenue collapse and slashed earnings guidance by nearly half. The stock plummeted 57.8% on May 5, 2026, from $9.25 to $3.90. The lawsuit alleges management knew of U.S. market weakness when reaffirming guidance between November 25, 2025 and February 5, 2026.

EMBC securities class action misleading guidance revenue collapse earnings miss shareholder losses pen needle business customer concentration risk

Sentiment note

The company is accused of issuing materially false or misleading statements about fiscal year 2026 performance. Actual results showed a 17.4% revenue decline versus promised flat-to-down-2%, adjusted EPS cut by ~43%, operating margins down ~700 basis points, and free cash flow reduced by roughly half. The stock experienced a severe 57.8% decline following the disclosure, and a securities class action has been filed alleging management knew of weakness when reaffirming guidance.

Negative Aug 3, 2026 • 23:34 UTC GlobeNewswire Inc. • Hagens Berman

EMBC 2-WEEK DEADLINE ALERT: Hagens Berman Investigates Alleged Securities Law Violations at Embecta Corp. (NASDAQ: EMBC) Following Pending Class Action Litigation

Hagens Berman is investigating Embecta Corp. for alleged securities law violations, claiming the company misrepresented the stability of its insulin pen needle business. On May 5, 2026, Embecta revealed significant revenue decline, slashed full-year EPS guidance by 43%, and cut its quarterly dividend by 93%, causing the stock to plummet 57.8% in a single trading day. The class action lawsuit covers the period from November 25, 2025 to May 4, 2026, with a lead plaintiff deadline of August 17, 2026.

EMBC securities fraud class action lawsuit misrepresentation insulin pen needle business revenue decline dividend cut stock plunge

Sentiment note

The company is facing a securities class action lawsuit for allegedly misleading investors about the stability of its core business. Management made false assurances about the pen needle portfolio while the company was experiencing significant competitive share loss and market volume softness. The subsequent disclosure of massive revenue decline, 43% EPS guidance cut, and 93% dividend reduction resulted in a 57.8% single-day stock plunge, indicating severe loss of investor confidence and potential financial distress.

Negative Aug 3, 2026 • 14:46 UTC GlobeNewswire Inc. • Schall, Brown & Schwartz Llp

EMBC Investors Have Opportunity to Lead Embecta Corp. Securities Fraud Lawsuit with SBS Law

Schall, Brown & Schwartz LLP has filed a class action lawsuit against Embecta Corp. (NASDAQ: EMBC) for alleged violations of securities laws. The lawsuit claims the company made false and misleading statements regarding its fiscal guidance for Q2 and full-year 2026, failing to disclose known market headwinds in the pen needle sector. The class period runs from November 25, 2025 to May 4, 2026, with a deadline of August 17, 2026 for shareholders to participate.

EMBC class action lawsuit securities fraud false guidance market headwinds pen needle market shareholder rights Securities Exchange Act

Sentiment note

The company is accused of making false and misleading statements about its financial guidance and failing to disclose known market headwinds that would impact performance. These allegations of securities fraud and investor deception warrant a negative sentiment rating.

Negative Aug 2, 2026 • 02:12 UTC GlobeNewswire Inc. • Rosen Law Firm

EMBECTA DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Embecta Corp. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – EMBC

Rosen Law Firm is notifying Embecta Corp. investors who purchased stock between November 25, 2025 and May 4, 2026 about a securities class action lawsuit. The lawsuit alleges that Embecta made false and misleading statements regarding its fiscal results and guidance, specifically touting its pen needle business as 'incredibly resolute' before missing expectations and cutting 2026 guidance. Investors with losses exceeding $100,000 are encouraged to join the class action before the August 17, 2026 lead plaintiff deadline.

EMBC securities class action misleading guidance investor losses pen needle business fiscal results class period

Sentiment note

The company is the subject of a securities class action lawsuit alleging it made false and misleading statements about its fiscal results and business performance. The company touted strong performance in its pen needle business before subsequently missing expectations and cutting guidance, resulting in investor losses.

Negative Jul 30, 2026 • 23:40 UTC GlobeNewswire Inc. • Hagens Berman

EMBC Alert: Hagens Berman Investigates Alleged Securities Law Violations at Embecta Corp. (NASDAQ: EMBC) Following Pending Class Action Litigation

Hagens Berman is investigating Embecta Corp. for alleged securities law violations, claiming the company misrepresented the stability of its insulin pen needle business. Embecta's stock plummeted 57.8% after revealing significant revenue decline, slashing full-year EPS guidance by 43% and cutting its quarterly dividend by 93%. The class action lawsuit covers the period from November 25, 2025 to May 4, 2026, with a lead plaintiff deadline of August 17, 2026.

EMBC securities fraud class action lawsuit insulin pen needle business misrepresentation revenue decline stock price decline dividend cut

Sentiment note

The company is under investigation for alleged securities law violations and material misrepresentations regarding its core business stability. Stock experienced a severe 57.8% single-day decline following disclosure of significant revenue shortfalls, massive EPS guidance cuts (43%), and dramatic dividend reduction (93%), indicating serious operational and financial deterioration.